NBEV - New Age Beverages Corporation

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.2900
-0.0900 (-3.78%)
At close: 4:00PM EST

2.3300 +0.04 (1.75%)
After hours: 7:56PM EST

Stock chart is not supported by your current browser
Previous Close2.3800
Open2.4500
Bid2.2900 x 4000
Ask2.3100 x 3200
Day's Range2.2800 - 2.4500
52 Week Range2.1000 - 7.7900
Volume2,086,251
Avg. Volume1,940,313
Market Cap179.522M
Beta (3Y Monthly)2.23
PE Ratio (TTM)N/A
EPS (TTM)-0.3580
Earnings DateNov 14, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.00
  • Yes, You Can Time the Market. Find out How - November 20, 2019
    Zacks

    Yes, You Can Time the Market. Find out How - November 20, 2019

    Is the ability to time the markets more of a data-driven science or a 'gut - feeling' art?

  • How this CBD company created a buzz by 'kind of making fun of millennial culture'
    Yahoo Finance

    How this CBD company created a buzz by 'kind of making fun of millennial culture'

    Ask Benjamin Witte about Recess, and one of the first places he’ll send you is the company’s Instagram page.

  • Investing.com

    New Age Beverages Tumbles as Earnings, Revenue Miss

    Investing.com - New Age Beverages (NASDAQ:NBEV) sank in midday trade on Thursday after its earnings came in lower than forecast.

  • GlobeNewswire

    NEWAGE REPORTS RECORD 3RD QUARTER SALES WITH REVENUE GROWTH OF 427%

    DENVER, COLORADO, Nov. 14, 2019 -- NEWAGE (NASDAQ: NBEV), the Colorado-based healthy products company, today announced financial results for the quarter ended September 30,.

  • 3 Pros, 3 Cons for New Age Beverages Stock
    InvestorPlace

    3 Pros, 3 Cons for New Age Beverages Stock

    Thanks to both Canadian legalization as well as the 2018 farm bill here in the states, North America has essentially become "little Amsterdam." Moreover, favorably shifting public sentiment in the U.S. has made cannabis-infused beverage companies like New Age Beverages (NASDAQ:NBEV) intriguing for both consumers and investors alike. Particularly, NBEV stock appeals for the underlying broad mixture of cannabis and general health-related drinks.Source: monticello / Shutterstock.com Still, cannabis stocks are infamous for their volatility. Due to myriad challenges, along with questions about the industry's financial viability, several investors have dumped out of their positions. Despite New Age Beverages stock not being a pure cannabis play, shares have not received an exemption from the pain. Naturally, investors remain unsure how to approach NBEV.Further adding to the pressure, New Age will release its third-quarter earnings results on Nov. 14 before the opening bell. Since Q2 2017, the company has failed to deliver positive earnings per share. As such, investors will likely want to see some meaningful pathway toward profitability for NBEV stock.InvestorPlace - Stock Market News, Stock Advice & Trading TipsGiven the rough waters of the broader cannabis industry, it's difficult to guess how the markets will respond on Thursday. Still, legal cannabis products, especially cannabis-infused beverages are incredibly popular. With that, here are three arguments for and against New Age Beverages stock: Pros: Strong Projected Growth for Cannabis BeveragesCannabis-based beverages, specifically cannabidiol or CBD-infused drinks, will be huge in the U.S. According to research firm Zenith Global, this market will hit a value of $1.4 billion at the end of 2023. To put this into context, Zenith projects CBD beverages to reach $227 million at the end of this year. * 7 Tech Stocks You Should Avoid Now In addition, companies like New Age have the opportunity to convert curious newcomers to cannabis-based products and therapies. According to an August 2019 Gallup poll, 14% of Americans say they use CBD. While impressive, this figure also leaves an ample opportunity for New Age to advantage, potentially lifting NBEV stock.Not only that, High Yield Insights performed a study revealing that the most popular CBD products are baked goods. Coming in second place are CBD gummies. While not beverages, these are consumable formats with which everyone is familiar.Therefore, it's not a stretch to assume that the folks who like CBD edibles will eventually make the switch to CBD-infused beverages. That's a potential net positive for New Age Beverages stock. Pros: American Market Wide Open for NBEV StockRecently, I interviewed Marty Sumichrast, chairman and co-CEO of cbdMD (NYSEAMERICAN:YCBD). In our long-format discussion, Sumichrast mentioned that the U.S. market is wide open. Furthermore, he argues that Americans prefer CBD to tetrahydrocannabinol (THC)-based botanicals.Combined with the company's impressive array of products, this dynamic places cbdMD in a position to become the dominant CBD brand in the U.S.As a shareholder of YCBD, I wish them well. However, because the U.S. market is so open without an established dominant player, it allows companies like New Age to carve out a niche in a specific sub-segment like CBD-infused beverages. Pros: New Age Beverage Stock Isn't a Pure Cannabis PlayAlthough heavily associated with CBD, NBEV stock isn't purely a CBD investment. And right now, I'd say that fact offers some key advantages.Namely, New Age hasn't followed its cannabis peers in aggressive fiscal maneuvering. Although the company hasn't been profitable in a while, you can clearly see the pathway to eventual profitability. Primarily, NBEV features strong revenue growth and reasonable expenses.Also, New Age has a relatively solid balance sheet, highlighted by nearly $84 million in cash and only $13.4 million in long-term debt. Combined with its long-term capital lease obligations, these liabilities amount to $60.5 million.Simply put, management isn't making wild swings. At this point, that's a positive for NBEV stock. Cons: Legal Uncertainty in U.S. CBD MarketDespite much potential, New Age hasn't yet entered the CBD-infused beverage space in the U.S. Why? Management has blamed a "murky" legal environment.I don't fault them. Under the 2018 farm bill, industrial hemp and hemp-derived products are legal for individuals to purchase. But that doesn't necessarily mean that CBD is legal. After all, cannabis is still considered a Schedule I drug.How do American companies get around this tricky situation? CBD derived from hemp is permissible under the farm bill. However, CBD from any other source -- even if it contains less than 0.3% THC as mandated by the law -- is illegal.Even when you have everything right, CBD laws are still very confusing and perhaps contradictory. Because of this uncertainty, New Age Beverages stock risks losing momentum to competitors. Cons: Too Many AssumptionsAs enticing as CBD beverages are, nobody really knows how the market will respond. Though enticing for those looking for a non-offensive way to enjoy cannabis, CBD-infused drinks could end up becoming a fad.More critically, CBD itself could also become a fad. While I don't think this will be the case, I concede that the medical community is hesitant about endorsing CBD. Further research is necessary for medical professionals to feel comfortable prescribing cannabidiol or other cannabis-based therapies.Until that happens, NBEV stock has a fundamental risk associated with it. Cons: Big-Name CompetitionAs with most good ideas, NBEV isn't the only one pursing cannabis-infused beverages. Several players are involved in the CBD beverage space, most notably the joint partnership between Molson Coors Brewing (NYSE:TAP) and Hexo (NYSE:HEXO).Depending on how popular CBD-infused beverages become, other big players might enter the space. This could either be positive for New Age Beverages stock (i.e., a buyout) or it could be negative. Frankly, if larger players enter the space, they could use their leverage to build out a new brand.Also, the fact that NBEV is stalling in the U.S. market isn't a great confidence booster. Final AssessmentNew Age Beverages stock is a risk, but a compelling one. With the right amount of luck, shares can take off thanks to its powerful CBD brand. And because the U.S. market is ripe for the taking, the possibilities are endless.However, NBEV stock falls short because of the legality issue of CBD. And while I'm enthusiastic about CBD-infused beverages, the industry has question marks about viability.Ultimately, though, a lot of the bad news is baked into the price. If you can stomach the risk, NBEV stock is worth a careful, measured shot.As of this writing, Josh Enomoto is long YCBD and HEXO. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Large-Cap Stocks to Give a Wide Berth * 7 Potential New Stocks That Should Not Go Public * 5 Chinese Stocks to Buy Surging Higher The post 3 Pros, 3 Cons for New Age Beverages Stock appeared first on InvestorPlace.

  • New Age Beverages (NBEV) to Post Q3 Earnings: What to Expect?
    Zacks

    New Age Beverages (NBEV) to Post Q3 Earnings: What to Expect?

    New Age Beverages' (NBEV) third-quarter 2019 results might reflect gains from buyouts and a robust brand portfolio. However, higher costs might remain deterrents.

  • CBD beverage founder: 'I want to be regulated'
    Yahoo Finance

    CBD beverage founder: 'I want to be regulated'

    Not nearly enough legislative ink has been spilled over the booming CBD industry, according to Benjamin Witte. 

  • Were Hedge Funds Right About Dumping New Age Beverages Corporation (NBEV)?
    Insider Monkey

    Were Hedge Funds Right About Dumping New Age Beverages Corporation (NBEV)?

    While the market driven by short-term sentiment influenced by the accomodative interest rate environment in the US, increasing oil prices and deteriorating expectations towards the resolution of the trade war with China, many smart money investors kept their cautious approach regarding the current bull run in the second quarter and hedging or reducing many of […]

  • GlobeNewswire

    NEW AGE ANNOUNCES TIMING FOR THIRD QUARTER 2019 FINANCIAL RESULTS CONFERENCE CALL

    DENVER, COLORADO, Nov. 07, 2019 -- New Age Beverages Corporation (NASDAQ: NBEV), the Colorado-based organic and natural products company, announced that it will hold an.

  • GlobeNewswire

    JULIE GARLIKOV JOINS NEWAGE AS CHIEF MARKETING OFFICER

    New Age Beverages Corporation (NBEV), the Colorado-based organic and natural products company, today announced that Julie Garlikov has joined NewAge as the newly appointed Chief Marketing Officer effective November 4, 2019. Ms. Garlikov brings over two decades of senior level marketing experience with world class packaged goods companies to NewAge. Most recently she served as Chief Marketing Officer for Shaklee, a leading natural nutrition company, and just prior was the Vice President and Global Head of Marketing for Rodan and Fields, a leading global skincare company.

  • CBD is ‘the caffeine of the 21st century’: Recess CEO
    Yahoo Finance

    CBD is ‘the caffeine of the 21st century’: Recess CEO

    The key to selling a CBD product is to not sell the CBD, according to Benjamin Witte.

  • GlobeNewswire

    Emerging Leaders Targeting Billion Dollar Opportunities: Ice Cream, CBD, Beverages, Cannabis and Augmented Reality

    CEO Interviews with: NBEV, NGTF  News & VIDEO from Investor Conferences: NEXCF, MDCL  NEW YORK, Oct. 29, 2019 -- Wall Street Reporter, the trusted name in financial news.

  • GlobeNewswire

    NEW AGE HEALTH SCIENCES LAUNCHES RADIATION PROTECTION AND HEARING HEALTH PRODUCTS IN JAPAN

    DENVER, COLORADO, Oct. 25, 2019 -- New Age Beverages Corporation (NASDAQ: NBEV), the Colorado-based organic and natural products company, today announced the launch of the.

  • If You Had Bought New Age Beverages (NASDAQ:NBEV) Shares Five Years Ago You'd Have Made 498%
    Simply Wall St.

    If You Had Bought New Age Beverages (NASDAQ:NBEV) Shares Five Years Ago You'd Have Made 498%

    While New Age Beverages Corporation (NASDAQ:NBEV) shareholders are probably generally happy, the stock hasn't had...

  • Aurora Cannabis Stock Is Still Not Worth a Buy
    InvestorPlace

    Aurora Cannabis Stock Is Still Not Worth a Buy

    If misery loves company, then Aurora Cannabis (NYSE:ACB) shareholders are far from alone. While marijuana stocks like ACB were soaring earlier in the year, several marijuana-related headwinds and dulling hype have since sent many of these stocks downward. But if new investors want to brave the risk and allow ACB stock to grow in their portfolio, a risk-adjusted long position in shares needs to be properly cultivated first.Source: Shutterstock From the largest producer Canopy Growth (NYSE:CGC) to a smaller and promising niche player like New Age Beverages (NASDAQ:NBEV), a risk-off attitude toward this emerging-but-still-very-dicey market has been pervasive.And Aurora stock has proven no exception to this pain.InvestorPlace - Stock Market News, Stock Advice & Trading TipsIt's also true that the loss in ACB stock's value hasn't been without justifiable cause either. Last month's worse-than-forecast quarterly results failed to deliver anything other than more supportive ammo for ACB bears. That's because it's hard for Aurora to be a winner right now. Given the difficult regulatory environment for the cannabis market -- one that also increasingly faces oversupply problems -- rising costs and lower margins, it's no wonder Aurora hasn't been able to stand up straight lately.Adding more pressure to Aurora Cannabis stock is the fact that one of its peers, Hexo (NYSE:HEXO), recently announced an revenue warning and guidance retraction and continued push-back toward cannabis due to vaping fatalities. All of these problems could reflect future struggles for ACB's business as well.And, looking at the stock chart below, we can clearly see the toll this decisively bearish sentiment has taken on Aurora stock. ACB Stock Monthly Chart But before we jump on the bearish train, it's important to take a closer look at the bigger picture in Aurora Cannabis.Although I've said it before, it's still very relevant to ACB stock and prospective ACB investors: Most of the market's greatest and most legendary investments, from Coca-Cola (NYSE:KO) to Apple (NASDAQ:AAPL) or Amazon (NASDAQ:AMZN), have had their own periods of overenthusiastic sentiment eventually getting the best of investors. * 10 Stocks to Sell Before December's Meltdown To that end, Aurora stock can't just be written off. But buying shares today isn't advised.Right now, ACB stock is controlled by bearish operators. Following September's post-earnings breakdown of the 62% level and trendline support, shares have cratered by roughly 35%. Most recently, the pressure has forced a combined failure of 2018's bottom and 76% support. And as bad as that is, it could get a good deal worse.There's little to suggest Aurora Cannabis stock price's bearish trend can't continue toward the 2017 low of $1.38. This marks the Fibonacci cycle low detailed on the monthly chart above. It's an important level to consider. Specifically, it's the bottom for shares following Wall Street's enthusiastic introduction to ACB stock in late 2016.Ultimately, there's no reason to start cherry picking for a bottom in ACB. Even an accumulation strategy could prove very painful if shares continue to trend lower toward a full 100% retracement.It's simply too early to know what will happen to Aurora Cannabis stock here.Therefore, my recommendation is to allow a confirmed candlestick reversal pattern and bullish stochastics crossover to be in place on the monthly chart before considering a purchase of ACB stock. In my view, this approach won't buy the absolute bottom.More important, the approach stands a much stronger chance of cultivating longer-term profits if history repeats itself or simply rhymes in a good way.Disclosure: Investment accounts under Christopher Tyler's management do not currently own positions in any securities mentioned in this article. The information offered is based upon Christopher Tyler's observations and strictly intended for educational purposes only; the use of which is the responsibility of the individual. For additional options-based strategies and related musings, follow Chris on Twitter @Options_CAT and StockTwits. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Stocks to Sell Before December's Meltdown * 7 Software Stocks to Buy for Growth * 3 Large-Cap Stocks to Buy After Earnings The post Aurora Cannabis Stock Is Still Not Worth a Buy appeared first on InvestorPlace.

  • New Age Beverages (NBEV): Don’t Chase Headlines
    TipRanks

    New Age Beverages (NBEV): Don’t Chase Headlines

    Probably no other stock reacts to positive headlines more than New Age Beverages (NBEV - price target), yet the stock trades at yearly low. The company remains highly promotional of future opportunities without necessarily delivering on those plans. The latest example again hurt retail investors that over reacted to the headlines.Nestea TweetOn October 16, New Age Beverages tweeted that “big news” was on the way with Nestea. The market naturally jumped on the concept that the news was somehow related to a new CBD drink with Nestea owned by Coca-Cola.While a CBD deal with Coke would be a potential game changer, investors should carefully trade any headlines not backed by actual results and performance. The company followed the next day with a tweet that Nestea Instant Sweet Iced Tea Mix was back.The stock soared nearly $1 or 31% to $3.59 on the initial tweet. Clearly, an ice tea mix was not what any investor would consider as “big news.” The stock closed on October 17 at $2.82 for a minimal gain from this headline grabbing tweet.History Of Missing TargetsAn investor reaching for major news from New Age Beverages was burned yet again. The stock reached nearly $8 in February on CBD hype despite the company never living up to expectations.The stock is now trading slightly above the 52-week low of $2.57 so investors should consider all of the other products promised as game changes that haven’t helped the business or the stock. One only needs to go back to the recent announcement of CBD approval in Japan or the previous Walmart (WMT) deal all burned investors falling for the headline hype while the actual results of the business missed targets.On September 24, New Age announced the Japanese Narcotics Control Division and the Japanese Ministry of Health had approved the launch of CBD products in Japan. The stock jumped to $3.39 on the news before dropping to the 52-week low within about a week on October 2.Back on April 8, the stock surged on news of an expanded distribution deal with Walmart. The large retailer agreed to distribute their Marley brand causing the stock to soar to $6.69. Within a month, New Age was trading back into the $4s before collapsing further into the $2s.During this process, the company has a long history of missing estimates. The Morinda deal was promoted as creating a business with substantial EBITDA profits, but analysts now forecast New Age losing money in both 2019 and 2020.The original 2019 revenue estimate surrounding the merger was $320 million. Now, despite the expanded distribution deal with Walmart and other retailers, analysts estimate revenues for the year down at only $274 million.TakeawayThe key investor takeaway is that New Age Beverages has a history of announcing major deals and big news that doesn’t always come to fruition. The bottom line is that investors should avoid this stock on any hype, especially around CBD beverages, until the company more consistently beats financial targets and more accurately reflects actual big news within press releases and social media.To find good ideas for cannabis stocks trading at fair value or better, visit TipRanks’ Best Stocks to Buy, a newly launched feature that unites all of TipRanks’ equity insights.Disclosure: No position

  • GlobeNewswire

    NEW AGE EXPANDS PARTNERSHIP WITH NESTLE S.A. TO RELAUNCH NESTEA POWDERED TEA IN THE UNITED STATES

    New Age Beverages Corporation (NBEV), the Colorado-based organic and natural products company, today announced the expansion of their partnership with Nestle, including the broadening of their license agreement on NESTEA to now include all products under the brand, including NESTEA Powdered Tea products in the United States. As a result, New Age is launching NESTEA Powders immediately in its e-commerce system, targeting its current database of more than 1,000,000 consumers, and with major retailers through the United States. NESTEA Powdered Tea has historically generated sales at retail of more than $30 million.

  • The Keys to Successfully Timing the Markets - October 01, 2019
    Zacks

    The Keys to Successfully Timing the Markets - October 01, 2019

    Have you ever dreamed of being that one in a million investor who has the talent to perfectly time the markets?

  • Is the Options Market Predicting a Spike in New Age Beverages (NBEV) Stock?
    Zacks

    Is the Options Market Predicting a Spike in New Age Beverages (NBEV) Stock?

    Investors need to pay close attention to New Age Beverages (NBEV) stock based on the movements in the options market lately.

  • CBD: Japan Welcomes NBEV, Stock Pops
    Market Realist

    CBD: Japan Welcomes NBEV, Stock Pops

    Today, New Age Beverages Corporation (NBEV) announced that it would launch its CBD (cannabidiol) based products. Share prices jumped by 14.96% to $3.20.

  • Benzinga

    Pure Global Cannabis Strikes Deal To Produce, Export CBD Products From Chinese Facility

    The Canadian LP announced that it has secured an agreement through its wholly owned subsidiary PureSinse Inc. with KMT-Hansa Corp., a Chinese hemp production company registered in Anguilla. “We are extremely excited to be the first Canadian LP to partner with a Chinese group seeking to develop a project of this scale in China. This strategic relationship gives us access to KMT’s resources and connections in China.

  • GlobeNewswire

    NEW AGE GAINS APPROVAL FROM JAPANESE GOVERNMENT TO LAUNCH CBD

    New Age Beverages Corporation (NBEV), the Colorado-based organic and natural products company, announced the approval by the Japanese Narcotics Control Division and the Japanese Ministry of Health for New Age’s CBD products in Japan and the company’s subsequent launch into the market effective immediately. New Age is the first major company to gain approval by the Japanese Ministry of Health and Narcotics Control Division to sell its portfolio of CBD products in the country.  New Age created a separate, wholly-owned subsidiary in 2018 under which it commercializes all of its CBD-infused products, including its line of Marley CBD-Infused Beverages and its portfolio of ‘Nhanced creams, oils, and roll-ons, and the forthcoming Noni+CBD product.

  • Are Insiders Selling New Age Beverages Corporation (NASDAQ:NBEV) Stock?
    Simply Wall St.

    Are Insiders Selling New Age Beverages Corporation (NASDAQ:NBEV) Stock?

    It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...

  • Why the Vaping Crisis Might Benefit CBD-infused New Age Beverages Stock
    InvestorPlace

    Why the Vaping Crisis Might Benefit CBD-infused New Age Beverages Stock

    Although not a pure cannabis play, New Age Beverages (NASDAQ:NBEV) has had to deal with the same volatility. Since January's opening price, NBEV stock has dropped a staggering 37%. However, the downfall isn't due to a lack of trying.Source: Shutterstock Early this year, NBEV announced an addition to its Marley-branded beverages called Marley+CBD. Infused with cannabidiol or CBD, the cannabis compound brought a therapeutic element to the artisanal beverage series. Plus, the positive notoriety associated with CBD gave New Age Beverages stock a nice lift following the announcement.This past summer, New Age CEO Brent Willis showcased the company's Nhanced CBD line of oils, creams and lotions. Launched in Hong Kong, NBEV intends to expand into Japan and China next.InvestorPlace - Stock Market News, Stock Advice & Trading TipsUnfortunately, NBEV stock peaked in early February. From then on, save for some smatterings of good news, it's been all downhill for shares.That said, New Age Beverages stock appears to have found a bottom around the psychologically significant $3 level. Granted, most conservative investors should ignore this technical phenomenon. But for the speculators among you, NBEV might be an interesting play.In a strange way, I say this because of the current vaping crisis. Federal health agencies are investigating a recent spike of acute lung illnesses which they believe are associated with vaping. However, evidence suggests that illicitly sourced THC-infused vaping liquids are the real culprit. * 10 Battered Tech Stocks to Buy Now In the context of companies like Cronos Group (NASDAQ:CRON), the vaping crisis is a distraction. For the time being, it's probably kept NBEV stock in check, too. But in the long run, this issue may benefit New Age Beverages. Here's why: A Platform Crisis Will Give Way to CuriosityOne of the challenges of cannabis-based companies is overcoming the stigma associated with the plant. Typically, the term "cannabis" conjures up images of stoners smoking, or in this case vaping a joint.As my InvestorPlace colleague Will Ashworth noted, vaping or smoking products will always be a tough sell, irrespective of alleged health benefits. But products like beverages, oils and creams? That is a much more palatable situation, one that clearly favors New Age Beverages stock.Recently, I had a chance to sit down with corporate representatives John Weston and Paul Dibrito of cbdMD (NYSEAMERICAN:YCBD). During our conversation, we discussed the wide-ranging product diversity of the CBD and hemp space. For instance, cbdMD features ample ways to enjoy hemp-based therapies beyond vaping. They also have a pet product division called Paw CBD.What does this have to do with NBEV stock and the vaping crisis? No matter what's going on right now, an increasing number of people are interested in CBD for therapeutic use. Sure, the vaping platform might take a hit (no pun intended) from the present crisis. But the core substance itself has substantial support.Therefore, it's much easier to evangelize the benefits of hemp-based products to your family and friends when using socially appropriate platforms. You might not be able to roll a fatty for grandma, no matter how much she complains of pain. But a capsule or a refreshing beverage? That's much easier to swallow (pun intended).Plus, not everyone is healthy enough to smoke or vape. For instance, more than 25 million Americans have asthma. Vaping might not be the best choice for them. But a CBD-infused beverage, as far as I'm aware, is consumable by nearly everyone. NBEV Stock and Long-Term AmbitionsInterestingly, NBEV CEO Willis was formerly a Coca-Cola (NYSE:KO) and Anheuser Busch Inbev (NYSE:BUD) executive. As you might imagine, he's now a strong advocate of legal cannabis.But Willis' push to drive into Asia strikes me as extremely ambitious. When he mentioned Japan, I rolled my eyes. This is the country that arrested and deported former Beatle Paul McCartney. * 7 Momentum Stocks to Buy On the Dip Moreover, when Canada legalized recreational marijuana, the Japanese government issued a stern warning to its citizens living abroad: don't touch the stuff or risk severe penalties.In my opinion, this was an empty threat. However, it does demonstrate Japanese society's highly conservative viewpoint toward the cannabis plant.Naturally, this is an uphill battle for New Age Beverages and NBEV stock. At the same time, if you're going to break into Asia, doing so with CBD-infused beverages probably gives you the best chance of success.But as I said earlier, that sentiment should apply to almost anyone. New Age Beverages stock is incredibly risky. Due to its palatable platform, though, it might have an outside chance of delivering the goods.As of this writing, Josh Enomoto did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Recession-Resistant Services Stocks to Buy * 7 Hot Penny Stocks to Consider Now * 7 Tech Stocks You Should Avoid Now The post Why the Vaping Crisis Might Benefit CBD-infused New Age Beverages Stock appeared first on InvestorPlace.

  • Juul's valuation tumbles 35% as CDC issues new vaping warning
    Yahoo Finance Video

    Juul's valuation tumbles 35% as CDC issues new vaping warning

    According to the Wall Street Journal a hedge fund that was an early investor in Juul recently wrote down its stake in the company to value Juul at just $24 billion dollars, a 35% drop from the $38 billion dollar valuation the company boasted just about a year ago when tobacco giant Altria paid up for a minority stake in the vaping giant. Yahoo Finance's Zack Guzman and Emily McCormick discuss with Barron's Senior Writer Alexandra Scaggs.